Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Juergen Froehlich
Observed names:
Froehlich J,
J Froehlich,
J. Froehlich
Institution:
Arcturus Therapeutics (United States)
Observed institutions:
National Institutes of Health,
Genentech,
Aradigm (United States),
Arcturus Therapeutics (United States),
Eunice Kennedy Shriver National Institute of Child Health and Human Development,
Technische Universität Dresden,
Stanford University
show all 7
OpenAlex ID:
A5091473499
Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: Results of a prospective randomized trial
1996
·
Fred A. Weaver
, Anthony J. Comerota
, et al.
·
Journal of Vascular Surgery
·
269
PDF
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
2019
·
Charles S Haworth
, Diana Bilton
, et al.
·
The Lancet Respiratory Medicine
·
242
PDF
Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts
1996
·
Anthony J. Comerota
, Fred A. Weaver
, et al.
·
The American Journal of Surgery
·
191
Evaluation of Early Computed Tomographic Findings in Acute Ischemic Stroke
1999
·
Michael P. Marks
, Eric B. Holmgren
, et al.
·
Stroke
·
155
The use of human recombinant gonadotropin receptors to search for immunoglobulin G-mediated premature ovarian failure
1995
·
J N Anasti
, M R Flack
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
67
Technical Evaluation of a New Immunoradiometric and a New Immunoluminometric Assay for Thyroglobulin
2002
·
Nils G Morgenthaler
, Juergen Froehlich
, et al.
·
Clinical Chemistry
·
63
Increased biological activity due to basic isoforms in recombinant human follicle-stimulating hormone produced in a human cell line
1994
·
M R Flack
, A P Bennet
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
58
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
2020
·
James D. Chalmers
, David Cipolla
, et al.
·
European Respiratory Journal
·
56
PDF
The United States Registry for Fibromuscular Dysplasia: Results in the First 447 Patients
2012
·
J.W. Olin
, J. Froehlich
, et al.
·
Journal of Vascular Surgery
·
50
WS10.03 Inhaled LUNAR®-CFTR mRNA (ARCT-032) is safe and well-tolerated: A phase 1 study
2024
·
D.E. Geller
, C. Crowley
, et al.
·
Journal of Cystic Fibrosis
·
16
Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection
2019
·
D.R. VanDevanter
, I. Gonda
, et al.
·
Clinical Microbiology and Infection
·
15
Emerging Opportunities for Inhaled Antibiotic Therapy
2015
·
Cipolla D
, Froehlich J
·
Journal of Antimicrobial Agents
·
8
PDF
Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
2020
·
James D. Chalmers
, David Cipolla
, et al.
·
European Respiratory Journal
·
4
283 Safety and tolerability of inhaled LUNAR-CFTR mRNA (ARCT-032) demonstrated in a Phase 1 study
2024
·
D. Geller
, C. Crowley
, et al.
·
Journal of Cystic Fibrosis
·
3
Open-label extension (OLE) of ORBIT-3 and ORBIT-4 trials of ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB)
2018
·
Anne O'Donnell
, Igor Gonda
, et al.
·
European Respiratory Journal
·
3
Comment on: Inhaled antimicrobial therapy—Barriers to effective treatment, by J. Weers, Inhaled antimicrobial therapy — Barriers to effective treatment, Adv. Drug Deliv. Rev. (2015), http://dx.doi.org/10.1016/j.addr.2014.08.013
2015
·
David Cipolla
, Juergen Froehlich
, et al.
·
Advanced Drug Delivery Reviews
·
3
Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline
2017
·
Juergen Froehlich
, Janice Dahms
, et al.
·
European Respiratory Journal
·
2
A Phase 3 Study Design of Pulmaquin® in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas aeruginosa (PA)
2016
·
A O'Donnell
, D Bilton
, et al.
·
Pneumologie
·
2
Inhaled Ciprofloxacin (ARD-3150) in Patients with Non-Cystic Fibrosis Bronchiectasis and Frequent Pulmonary Exacerbations: A Pooled Analysis from ORBIT-3 and ORBIT-4
2019
·
J.D. Chalmers
, A.M. Davis
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
1
Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA)
2018
·
James D. Chalmers
, Bruce Thompson
, et al.
·
European Respiratory Journal
·
1
Reduction of pulmonary exacerbations in two phase 3 Trials: in-depth analyses
2018
·
David Cipolla
, Angela Davis
, et al.
·
European Respiratory Journal
·
1
Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections
2018
·
Anne O'Donnell
, Juergen Froehlich
, et al.
·
European Respiratory Journal
·
1
Two Randomised Controlled Trials of Inhaled Liposomal Ciprofloxacin (ARD-3150) in Patients with Non-Cystic Fibrosis Bronchiectasis and Chronic Lung Infection with Pseudomonas Aeruginosa
2018
·
Charles Haworth
, Diana Bilton
, et al.
·
SSRN Electronic Journal
·
1
Interim results of phase 2 trial of ARCT-810 MRNA therapy in patients with ornithine transcarbamylase deficiency
2026
·
Ben Greener
, Rachael Batabyal
, et al.
·
Molecular Genetics and Metabolism
The rehaVital Stroke Network: An integrated, post-discharge, patient care model initiated by durable medical equipment specialists.
2014
·
Juergen Froehlich
, Karen Harbeck
, et al.
·
PubMed
Show more works
View as search
Works count:
26
Citation count:
1,212
H-index:
11
I10-index:
11
Year
Topic
Type